Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Supernus Pharmaceuticals achieves record revenues, faces generic competition in 2022

Supernus Pharmaceuticals delivered a strong financial performance in 2022, driven by record revenues and successful product launches.
While facing challenges from generic competition, the company's focus on growth brands and pipeline assets offers opportunities for future expansion and innovation.
Strategic financial management and market adaptation will be crucial for Supernus Pharmaceuticals to navigate challenges and capitalize on growth prospects in 2023.
With a solid financial foundation and a commitment to innovation, the company is poised to pursue growth opportunities and enhance shareholder value in the pharmaceutical sector.

Supernus Pharmaceuticals reports Q1 revenue growth, faces Trokendi XR challenges

Supernus Pharmaceuticals delivered a mixed performance in Q1 2023, with strong revenue but challenges in Trokendi XR sales.
The company's financial strength, strategic guidance revisions, and pipeline progress position it for future growth.
Opportunities lie in leveraging cash reserves, driving key product sales, and advancing pipeline programs for sustained growth.
Addressing challenges in Trokendi XR sales and maintaining competitive positioning will be crucial for Supernus Pharmaceuticals' success.

Supernus Pharmaceuticals reports Q2 growth driven by Qelbree success

Supernus Pharmaceuticals showcased strong performance in Q2 2023, driven by Qelbree and GOCOVRI growth, despite Trokendi XR sales decline.
While facing challenges with Trokendi XR, the company's pipeline progress and strategic focus on key products offer growth opportunities.
Management's financial guidance reiteration for 2023 reflects confidence in the company's ability to navigate challenges and capitalize on strengths.
Overall, Supernus Pharmaceuticals remains positioned for growth through product innovation and market expansion strategies.

Supernus Pharmaceuticals reports robust Q3 performance amidst revenue challenges

Supernus Pharmaceuticals delivered a strong performance in Q3 2023 driven by Qelbree and GOCOVRI, showcasing revenue growth and promising product milestones.
While facing challenges with Trokendi XR sales decline and financial losses, the company maintains a positive outlook with revised full-year guidance and a solid cash position.
Opportunities lie in leveraging product strengths, advancing pipeline studies, and utilizing available resources to sustain growth and navigate challenges effectively.

Supernus Pharmaceuticals reports robust earnings, eyes CNS market expansion

Supernus Pharmaceuticals delivered strong financial performance in Q4 2023 and full year 2023, supported by record sales and stable earnings.
The company's transition to growth products, strong cash reserves, and strategic focus on CNS present a promising outlook for future growth.
While challenges exist in product transitions and market dynamics, Supernus is well-positioned to capitalize on opportunities in the CNS space.
By leveraging its strengths, addressing challenges, and seizing opportunities, Supernus Pharmaceuticals aims for sustained growth and market leadership.

Supernus Pharmaceuticals reports robust Q1 performance amidst pipeline opportunities

Supernus Pharmaceuticals demonstrated strong performance in Q1 2024, driven by Qelbree's growth, while facing challenges in the Parkinson's franchise.
The company's financial stability is evident with a healthy cash position and reiterated full-year revenue guidance.
Exciting opportunities exist in the CNS pipeline, but addressing setbacks like the FDA response for SPN-830 is crucial.
Strategic actions are needed to navigate the impact of generics on existing products and capitalize on upcoming catalysts.

Supernus Pharmaceuticals reports strong Q2 earnings and raises 2024 guidance

Supernus Pharmaceuticals demonstrated solid financial performance and growth in Q2 2024, driven by key products and pipeline advancements.
While facing regulatory uncertainties and operational challenges, the company's strong cash position and raised guidance signal resilience and strategic foresight.
Opportunities lie in expanding the CNS pipeline, optimizing gross-to-net deductions, and leveraging financial strength for future growth initiatives.

Supernus Pharmaceuticals reports strong Q3 performance and raises revenue guidance

Supernus Pharmaceuticals demonstrated robust financial performance and product growth in Q3 2024, driven by key products and pipeline advancements.
While facing challenges with certain product sales and pricing strategies, the company remains well-positioned for future opportunities and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree® (viloxazine extended-release capsules) has been accepted for review by Health Canada. Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New York City.

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United Kingdom.

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities.

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen David Amsellem – Piper Sandler Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to loss of $0.29 per share a year ago.

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced data in a poster presentation at Psych Congress 2024 with new data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder (MDD).

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024.

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:30 p.m. ET to discuss the topline data Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025 ROCKVILLE, Md.

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder.

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder (ADHD), bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her.

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate virtually in a fireside chat at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit on Thursday, September 26, 2024, at 8:40 a.m. ET.

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable.

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts.

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD).

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Stacy Ku - TD Cowen Annabel Samimy - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago.

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter of 2024 and associated Company developments.

Supernus Announces Second Quarter 2024 Financial Results

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD).

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024.

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Gilead Sciences

Jazz Pharmaceuticals

When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry's winners.

News for Supernus Pharmaceuticals Stock (SUPN)